Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: A pairwise and network meta-analysis

Diabetes Research and Clinical Practice

Volumn 98, Issue 3, 2012, Pages 386-395

  Sun, Feng ^a,b,c   Yu, Kai ^d   Wu, Shanshan ^a   Zhang, Yuan ^a   Yang, Zhirong ^a   Shi, Luwen ^b   Ji, Linong ^e   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

^c SHIHEZI UNIVERSITY   (China)

^d TIANJIN FIFTH CENTRAL HOSPITAL   (China)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Cardiovascular safety; Efficacy; Glucagon like peptide 1 receptor agonists; Network meta analysis; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; TASPOGLUTIDE;

ADULT; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON;

EID: 84870681188     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.09.004     Document Type: Review

References (51)

1. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
2. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46:3-19.
3. Scheen A.J. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?. Diabetes Metab 2007, 33:3-12.
4. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44:1249-1258.
5. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
6. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007, 23:945-952.
7. Pratley R.E. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 2008, 10:171.
8. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
9. Hansen K.B., Knop F.K., Holst J.J., Vilsboll T. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Int J Clin Pract 2009, 63:1154-1160.
10. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88.
11. Neumiller J.J., Campbell R.K. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009, 43:1433-1444.
12. Matthews J.E., Stewart M.W., De Boever E.H., Dobbins R.L., Hodge R.J., Walker S.E., et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:4810-4817.
13. Retterstol K. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert Opin Investig Drugs 2009, 18:1405-1411.
14. Christensen M., Knop F.K., Holst J.J., Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009, 12:503-513.
15. Umpierrez G.E., Blevins T., Rosenstock J., Cheng C., Anderson J.H., Bastyr E.J., et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011, 13:418-425.
16. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
17. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246.
18. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
19. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
20. Ratner R., Han J., Nicewarner D., Yushmanova I., Hoogwerf B.J., Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011, 10:22.
21. Marso S.P., Lindsey J.B., Stolker J.M., House J.A., Martinez Ravn G., Kennedy K.F., et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011, 8:237-240.
22. Monami M., Cremasco F., Lamanna C., Colombi C., Desideri C.M., Iacomelli I., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:1-10.
23. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009, 160:909-917.
24. Norris S.L., Lee N., Thakurta S., Chan B.K. Exenatide efficacy and safety: a systematic review. Diabet Med 2009, 26:837-846.
25. Shyangdan D.S., Royle P., Clar C., Sharma P., Waugh N., Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011, CD006423.
26. Shyangdan D.S., Royle P.L., Clar C., Sharma P., Waugh N.R. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010, 10:20.
27. Li W.X., Gou J.F., Tian J.H., Yan X., Yang L. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Curr Ther Res 2010, 71:211-238.
28. Montanya E., Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009, 31:2472-2488.
29. Henry R.R., Buse J.B., Sesti G., Davies M.J., Jensen K.H., Brett J., et al. Efficacy of anthiyperglycemic therapies and the influence of baseline hemoglobin A1C: a meta-analysis of the liraglutide development program. Endocr Pract 2011, 17:906-913.
30. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
31. Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Food and Drug Administration; December 2008.
32. Keus F., Wetterslev J., Gluud C., Gooszen H.G., van Laarhoven C.J. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol 2009, 104:546-551.
33. Fleiss J.L. The statistical basis of meta-analysis. Stat Methods Med Res 1993, 2:121-145.
34. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
35. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
36. Ades A.E., Sculpher M., Sutton A., Abrams K., Cooper N., Welton N., et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006, 24:1-19.
37. Salanti G., Marinho V., Higgins J.P. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 2009, 62:857-864.
38. Spiegelhalter D.J., Best N.G., Carlin B.P., Van Der L.A. Bayesian measures of model complexity and fit. J R Stat Soc B 2002, 64:583-639.
39. Best J.H., Hoogwerf B.J., Herman W.H., Pelletier E.M., Smith D.B., Wenten M., et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011, 34:90-95.
40. Jose T., Inzucchi S.E. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 2012, 9:109-116.
41. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
42. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
43. Anagnostis P., Athyros V.G., Adamidou F., Panagiotou A., Kita M., Karagiannis A., et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011, 13:302-312.
44. Chilton R., Wyatt J., Nandish S., Oliveros R., Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med 2011, 124:S35-S53.
45. Parks M., Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med 2010, 362:774-777.
46. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results - a long-term evaluation (LEADERTM). , http://clinicaltrials.gov/.
47. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. , http://clinicaltrials.gov/.
48. Zinman B., Schmidt W.E., Moses A., Lund N., Gough S. Achieving a clinically relevant composite outcome of an HbA1c of<7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012, 14:77-82.
49. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
50. Rosenstock J., Reusch J., Bush M., Yang F., Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009, 32:1880-1886. Albiglutide Study Group.
51. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900.